Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

May 25, 2018

Study Completion Date

May 25, 2018

Conditions
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Interventions
BIOLOGICAL

ALX-0171 3.0 mg/kg

BIOLOGICAL

ALX-0171 6.0 mg/kg

BIOLOGICAL

ALX-0171 9.0 mg/kg

OTHER

Placebo

Trial Locations (74)

Unknown

Investigator site 2, Brussels

Investigator site, Brussels

Investigator Site, Edegem

Investigator Site, Leuven

Investigator site, Roeselare

Investigator Site, Kozloduy

Investigator Site, Plovdiv

Investigator Site, Rousse

Investigator Site, Sofia

Investigator Site, Stara Zagora

Investigator Site, Santiago

Investigator site, Valdivia

Investigator Site, Floridablanca

Investigator Site 1, Medellín

Investigator site 2, Medellín

Investigator site, Santiago de Cali

Investigator site, Čakovec

Investigator site, Osijek

Investigator site, Slavonski Brod

Investigator site, Varaždin

Investigator site 1, Zagreb

Investigator site 2, Zagreb

Investigator site 3, Zagreb

Investigator site 4, Zagreb

Investigator site, Hradec Králové

Investigator Site, Tartu

Investigator site, Bochum

Investigator site, Dresden

Investigator Site, Sankt Augustin

Investigator Site, Wuppertal

Investigator Site, Balassagyarmat

Investigator site 1, Budapest

Investigator Site 2, Budapest

Investigator Site 3, Budapest

Investigator Site 4, Budapest

Investigator site, Debrecen

Investigator Site, Szeged

Investigator site, Székesfehérvár

Investigator Site, Veszprém

Investigator site, Beersheba

Investigator site, Haifa

Investigator site, Petah Tikva

Investigator Site, Daugavpils

Investigator Site, Riga

Investigator site, George Town

Investigator Site, Kuala Lumpur

Investigator Site, Seremban

Investigator Site, Sibu

Investigator Site, Alabang

Investigator site, Manila

Investigator Site 1, Quezon City

Investigator Site 2, Quezon City

Investigator site, Lublin

Investigator site, Trzebnica

Investigator site, Banská Bystrica

Investigator site, Bratislava

Investigator site, Košice

Investigator Site, Poprad

Investigator Site 1, Barcelona

Investigator Site 2, Barcelona

Investigator Site 3, Barcelona

Investigator Site, Bilbao

Investigator Site, El Palmar

Investigator site 1, Madrid

Investigator Site 2, Madrid

Investigator Site, Málaga

Investigator site, Santiago de Compostela

Investigator site, Seville

Investigator Site, Valencia

Investigator Site 1, Bangkok

Investigator site 2, Bangkok

Investigator Site, Chiang Mai

Investigator site, Hat Yai

Investigator Site, Khon Kaen

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT02979431 - Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection | Biotech Hunter | Biotech Hunter